Skip to main content
OpenTrials
Completed

NCT Number: NCT02638207

Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

MHAT Puls EOOD, Blagoevgrad, Bulgaria

Loading trial locations.

About this study

Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy ("ProCID trial")

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with diagnosis of definite or probable Chronic inflammatory demyelinating polyneuropathy (CIDP) according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) Guideline 2010 [van den Bergh et al., 2010]; including patients with Multifocal Acquired Demyelinating Sensory And Motor Neuropathy (MADSAM) or pure motor Chronic inflammatory demyelinating polyneuropathy (CIDP )
  • Patients currently depending on treatment with immunoglobulins or corticosteroids
  • Patients with active disease, i.e. not being in remission, who are progressive or relapsing prior to trial start or during the Wash-out Phase
  • Weakness of at least 2 limbs
  • >18 to <80 years of age
  • Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 (with a score of 2 coming exclusively from leg disability)
  • Voluntarily given, fully informed written consent obtained from patient before any study-related procedures are conducted

Exclusion criteria

  • Unifocal forms of Chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Pure sensory Chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Multifocal motor neuropathy (MMN) with conduction block [van den Bergh et al., 2010]
  • Patients who previously failed immunoglobulin treatment
  • Treatment with immunomodulatory/suppressive agents (cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil or azathioprine) during the six months prior to baseline visit
  • Patients on or treated with rituximab, alemtuzumab, cyclophosphamide, or other intensive chemotherapeutic regimens, previous lymphoid irradiation or stem cell transplantation during the 12 months prior to baseline visit
  • Respiratory impairment requiring mechanical ventilation
  • Myelopathy or evidence of central nervous system demyelination or significant persisting neurological deficits from stroke, or central nervous system (CNS) trauma
  • Clinical evidence of peripheral neuropathy from another cause such as
  • connective tissue disease or systemic lupus erythematosus (SLE)
  • HIV infection, hepatitis, Lyme disease
  • cancer (with the exception of basal cell skin cancer)
  • IgM paraproteinemia with anti-myelin associated glycoprotein antibodies
  • Diabetic neuropathy
  • Cardiac insufficiency (New York Heart Association [NYHA] III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease
  • Severe liver disease (ALAT 3x > normal value)
  • Severe kidney disease (creatinine 1.5x > normal value)
  • Hepatitis B, hepatitis C or HIV infection
  • Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever; patients with susceptibility to embolism or deep vein thrombosis (DVT)
  • Body mass index (BMI) ≥40 kg/m2
  • Patients with uncompensated hypothyroidism (abnormally high Thyroid-Stimulating Hormone [TSH] and abnormally low Thyroxine [T4]) or known vitamin B12 deficiency if patients don't receive adequate substitution therapy
  • Medical conditions whose symptoms and effects could alter protein catabolism and/or Immunoglobulin G (IgG) utilization (e.g. protein-losing enteropathies, nephrotic syndrome)
  • Known Immunoglobulin A (IgA) deficiency with antibodies to Immunoglobulin A (IgA)
  • History of severe hypersensitivity, e.g. anaphylaxis or severe systemic response to immuno-globulin, blood or plasma derived products, or any component of NewGam
  • Known blood hyperviscosity, or other hypercoagulable states
  • Use of other blood or plasma-derived products within three months prior to Visit 2
  • Patients with a past or present history of drug abuse or alcohol abuse within the preceding five years prior to baseline visit
  • Patients unable or unwilling to understand or comply with the study protocol
  • Participation in another interventional clinical study with investigational medicinal product (IMP) treatment currently or during the three months prior to Visit 2
  • Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective birth control method (such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner) while on study

Treatment and study plan

NewGam

Drug

In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding

Other names: Panzyga

Primary outcomes

  1. Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

    Time frame: at Week 24

    Efficacy - Proportion of responders in the 1.0 g/kg NewGam arm at Week 24 (Termination Visit) relative to baseline (Week 0). A responder being defined as a patient with a decrease of at least 1 point on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score (a scale from 0 to 10, from healthy to unable to make any purposeful movements with arms and/or legs)

Secondary outcomes

  1. Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

    Time frame: at Week 24

    Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline compared to the 1.0 g/kg arm, based on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score

  2. Grip Strength Score

    Time frame: at Week 24

    Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the grip strength (Martin Vigorimeter) using the previously published minimum clinically important difference (MCID) cut-off of 8 kilopascal (kPa)

  3. Inflammatory Rasch-built Overall Disability Scale (I-RODS Score)

    Time frame: at Week 24

    Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the Inflammatory Rasch-built overall disability scale (I-RODS Score) using the MCID concept related to the varying standard errors (MCID-SE) as recently demonstrated

  4. Worsening in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

    Time frame: Week 24

    Time to first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale by at least 1 point from the value at baseline (Week 0)

  5. Mean Change in Grip Strength

    Time frame: Up to 24 weeks

    Mean change from baseline (Week 0) to Termination Visit in grip strength of both hands (assessed by Martin vigorimeter). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

  6. Inflammatory Rasch-built Overall Disability Scale (I-RODS)

    Time frame: Up to 24 weeks

    Mean change from baseline (Week 0) to Termination Visit in Inflammatory Rasch-built overall disability sum score (I-RODS using the concept of MCID-SE as recently reported) and number of improvers. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

    A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome.

  7. Motor Nerves

    Time frame: Up to 24 weeks

    Mean change from baseline (Week 0) to Termination Visit in sum of the distal evoked amplitude of 4 right sided and 4 left sided motor nerves (peroneal, tibial, ulnar and median). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

  8. Mean Change in Pain Intensity Numerical Rating Scale (PI-NRS Scale)

    Time frame: Up to 24 weeks

    Mean change from baseline (Week 0) to Termination Visit in Pain Intensity Numeric Rating Scale (PI-NRS). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

    The Pain Intensity Numeric Rating Scale (PI-NRS, a numeric scale where 0 = no pain and 10 = worst possible pain) is an 11-point scale for patient self-reporting of pain. A higher value represents a worse outcome.

  9. Worsening on the Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)

    Time frame: 24 weeks

    Time to first confirmed worsening on the I-RODS scale. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome.

    Worsening is determined using the concept of MCID (minimum clinically important difference) using the individually obtained standard errors (MCID-SE).

  10. 1 Point Decrease in the INCAT Disability Score

    Time frame: 24 weeks

    Time to 1 point decrease (improvement of disability) in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score

  11. Decrease in Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)

    Time frame: 24 weeks

    Time to decrease in Inflammatory Rasch-built overall disability scale (I-RODS) scores

Sponsors and collaborators

Lead sponsor

Octapharma

Industry

Registry information

Official study title

Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Acronym: CIDP

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Dec 23, 2015
Registry last updated
Feb 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.